Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate
- PMID: 2113003
- DOI: 10.1007/BF01417564
Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate
Abstract
Nitrates are highly effective both in terminating acute attacks of angina pectoris and in the prophylaxis of symptomatic and asymptomatic myocardial ischemia. Preload reduction by venodilatation is the prevailing mechanism of nitrates in patients with chronic stable angina and is the unique feature distinguishing them from beta and calcium-channel blockers. Nitrates dilate coronary arteries not only in pre- and poststenotic vessels, but also in eccentric lesions. In patients with endothelial dysfunction, nitrates seem to be the physiological substitute for endothelium-derived relaxing factor. During the past decade, however, there has been substantial evidence of a clinically relevant loss of the anti-ischemic effects ("nitrate tolerance"). Many studies with oral dosing of isosorbide dinitrate or isosorbide-5-mononitrate at least three times daily have proven nitrate tolerance in patients with coronary artery disease and/or congestive heart failure. Complete loss of anti-ischemic effects after repetitive, continuous patch attachments has also been found. As we first showed in 1983, intermittent therapy with once-daily ingestion of high-dose sustained-release isosorbide dinitrate was successful in preventing the development of tolerance. Similarly, tolerance to isosorbide-5-mononitrate also does not develop when it is ingested once daily. It is now generally accepted that a daily low-nitrate interval is required to prevent tolerance development. Although the minimal patch-free interval required to prevent tolerance needs further investigation, a 12-h patch-free interval should prevent tolerance in most patients. The prolonged duration of action of once-daily high-dosage administration of sustained-release formulations, the improved patient compliance with a single daily administration, and the increased likelihood of maximal anti-ischemic effects are important reasons for recommending high single daily doses of isosorbide dinitrate or isosorbide-5-mononitrate.
Similar articles
-
Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate.J Cardiovasc Pharmacol. 1999 Aug;34 Suppl 2:S21-7; discussion S29-31. doi: 10.1097/00005344-199908002-00005. J Cardiovasc Pharmacol. 1999. PMID: 10499557 Review.
-
Short and long-acting oral nitrates for stable angina pectoris.Cardiovasc Drugs Ther. 1994 Aug;8(4):611-23. doi: 10.1007/BF00877415. Cardiovasc Drugs Ther. 1994. PMID: 7848896 Review.
-
Glyceryl trinitrate (nitroglycerin) and the organic nitrates. Choosing the method of administration.Drugs. 1987 Sep;34(3):391-403. doi: 10.2165/00003495-198734030-00005. Drugs. 1987. PMID: 3119308 Review.
-
Induction and circumvention of nitrate tolerance applying different dosage intervals.Am J Med. 1987 Nov;83(5):860-70. doi: 10.1016/0002-9343(87)90643-7. Am J Med. 1987. PMID: 3674093
-
Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure.Cardiovasc Drugs Ther. 1997 Jan;10(6):735-42. doi: 10.1007/BF00053031. Cardiovasc Drugs Ther. 1997. PMID: 9110117 Review.
Cited by
-
Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Crit Care Res Pract. 2012;2012:290805. doi: 10.1155/2012/290805. Epub 2012 Feb 28. Crit Care Res Pract. 2012. PMID: 22482042 Free PMC article.
-
Stimulators of soluble guanylyl cyclase: future clinical indications.Ochsner J. 2013 Spring;13(1):147-56. Ochsner J. 2013. PMID: 23532174 Free PMC article.
-
Transdermal nitroglycerin (glyceryl trinitrate). A review of its pharmacology and therapeutic use.Drugs. 1990 Dec;40(6):880-902. doi: 10.2165/00003495-199040060-00009. Drugs. 1990. PMID: 2127741 Review.
-
Maternal Venous Hemodynamic Dysfunction in Proteinuric Gestational Hypertension: Evidence and Implications.J Clin Med. 2019 Mar 11;8(3):335. doi: 10.3390/jcm8030335. J Clin Med. 2019. PMID: 30862007 Free PMC article. Review.
-
Response to changing plasma concentrations of isosorbide-bound NO2 during acute and sustained treatment with isosorbide dinitrate in patients with coronary artery disease.Clin Cardiol. 2000 Jun;23(6):427-32. doi: 10.1002/clc.4960230610. Clin Cardiol. 2000. PMID: 10875033 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous